Sunshine Lake Pharma Co Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of multiple sclerosis, psoriasis, rheumatoid arthritis, atopic dermatitis, scleroderma, lupus nephritis, systemic lupus erythematosus and ulcerative colitis, among others.
The first patenting to emerge from Filtro Medical Inc. describes the development of blood filtration devices designed to reduce systemic exposure to chemotherapy or other therapeutic agents that have been delivered into a target treatment location.
Scientists at Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged transcriptional coactivator YAP1 or TAZ/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.
Scientists at Shanghai Haiyan Pharmaceutical Technology Co. Ltd. and Yangtze River Pharmaceutical Group have identified high affinity nerve growth factor receptor (NTRK1; TrkA) inhibitors reported to be useful for the treatment of pain, cancer, inflammation and neurodegenerative diseases.
Onquality Pharmaceuticals China Ltd. has synthesized prodrugs of tofacitinib acting as JAK inhibitors reported to be useful for the treatment of atopic dermatitis, psoriasis and alopecia areata.
Baylor College of Medicine has disclosed proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to Bruton tyrosine kinase (BTK)-, DNA-binding protein Ikaros (IKZF1)- and Zinc finger protein Aiolos (IKZF3)-targeting moieties through a linker.
RSS
